Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2025)

Indivior Pharmaceuticals has reported Common Equity over the past 5 years, most recently at -$98.0 million for Q4 2025.

  • Quarterly results put Common Equity at -$98.0 million for Q4 2025, up 70.92% from a year ago — trailing twelve months through Dec 2025 was -$98.0 million (up 70.92% YoY), and the annual figure for FY2025 was -$98.0 million, up 70.92%.
  • Common Equity for Q4 2025 was -$98.0 million at Indivior Pharmaceuticals, up from -$207.0 million in the prior quarter.
  • Over the last five years, Common Equity for INDV hit a ceiling of $121.0 million in Q4 2021 and a floor of -$337.0 million in Q4 2024.
  • Median Common Equity over the past 5 years was -$207.0 million (2025), compared with a mean of -$183.1 million.
  • Biggest five-year swings in Common Equity: tumbled 1126.67% in 2023 and later skyrocketed 70.92% in 2025.
  • Indivior Pharmaceuticals' Common Equity stood at $121.0 million in 2021, then plummeted by 112.4% to -$15.0 million in 2022, then tumbled by 1126.67% to -$184.0 million in 2023, then plummeted by 83.15% to -$337.0 million in 2024, then skyrocketed by 70.92% to -$98.0 million in 2025.
  • The last three reported values for Common Equity were -$98.0 million (Q4 2025), -$207.0 million (Q3 2025), and -$257.0 million (Q2 2025) per Business Quant data.